{"publication_id":"4753c82f-24d3-490c-8a23-6cc8d4194c24","screening":{"identified":51,"screened":51,"excluded":0,"included":51,"included_or_retained":51,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"51 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["Mechanistic data remain provocative but indirect: PCSK9 inhibition appears to attenuate vascular aging markers and efferocytosis defects in preclinical models, and a systematic review of vascular aging reported that patients with higher pulse wave velocity had approximately 46.2% increased risk of poor functional outcomes and 12.7% higher mortality after acute ischemic stroke.","The question of whether lipid-lowering therapies can extend human healthspan has gained urgency as populations age and cardiovascular disease remains the leading cause of death worldwide. PCSK9 inhibitors, a class of monoclonal antibodies that dramatically reduce low-density lipoprotein cholesterol, have been proposed as candidates for lifespan extension beyond their primary cardiovascular indications. The rationale linking PCSK9 inhibitors longevity rests on the observation that sustained LDL-C reduction may attenuate atherosclerotic burden and vascular aging, processes closely intertwined with functional decline in older adults (Kakaletsis 2024). Yet the clinical stakes are high: if these agents offer only narrow cardioprotection without broader geroprotective effects, the cost-benefit calculus for widespread deployment in aging populations remains uncertain. Early pharmacovigilance data suggest a largely acceptable safety profile (Zhang 2015), but whether safety in middle-aged cardiovascular cohorts translates to tolerability in the oldest-old is unproven. The PCSK9 inhibitors longevity hypothesis therefore represents a testable intersection of cardiovascular medicine and geroscience that demands rigorous evidence synthesis.","The geroscience hypothesis posits that targeting fundamental biological aging processes—rather than individual diseases in isolation—may yield multiplicative health benefits across organ systems. Within this framework, PCSK9 inhibitors longevity represents a repurposing strategy: a drug class developed for hypercholesterolemia is evaluated for effects that may extend beyond lipid metabolism to vascular aging, inflammation, and neuroprotection. Preclinical evidence suggests PCSK9 inhibition may influence endothelial efferocytosis and inflammatory signaling (Liu 2023; DOnofrio 2023), pathways implicated in age-related vascular stiffening and atherosclerosis progression. However, mechanistic plausibility alone is insufficient; the translation from mouse models to human aging trajectories remains an open question (Ioannidis 2005). The appeal of repurposing lies in the existing regulatory approval and clinical familiarity with alirocumab and evolocumab, yet their long-term effects on aging biomarkers and functional endpoints have not been systematically characterized. Whether PCSK9 inhibitors longevity can meaningfully modulate the hallmarks of aging in humans, or merely delay one downstream consequence, remains uncertain.","Several unresolved questions constrain the interpretation of PCSK9 inhibitors longevity evidence for aging populations. First, the mechanistic translation from lipid lowering to vascular aging attenuation remains poorly characterized: while preclinical studies suggest PCSK9 inhibition may reduce inflammatory biomarkers and improve endothelial function (Rehues 2023), human data are limited to short-term biomarker endpoints. Second, population specificity is a major gap: most trials enrolled middle-aged adults with established cardiovascular disease, and the applicability to frail, multimorbid, or very old individuals remains uncertain (Theodorou 2025). Third, dose-response and duration effects on aging outcomes are unknown, with existing trials typically limited to 2-5 years of follow-up. The PCSK9 inhibitors longevity hypothesis thus faces a translation gap between cardiometabolic efficacy and demonstrated geroprotective benefit.","This synthesis addresses the cross-domain tensions in PCSK9 inhibitors longevity evidence by separating mechanistic plausibility from clinical outcome data and weighting evidence according to outcome class and study design. The curated corpus of 51 reference papers reveals a pattern of positive signals in mortality-survival and contextual outcomes coexisting with predominantly null or mixed findings in safety-comorbidity and cardiometabolic domains. Structured evidence mapping identifies cross-study disagreements across outcome classes, with disagreement severity ranging from mild (severity 1) to substantial (severity 4) on key questions such as cognitive safety and vascular aging biomarkers. Our approach explicitly addresses the Ioannidis 2005 concern that surrogate endpoint associations may not guarantee hard-outcome validity by requiring triangulation across mechanistic, biomarker, and clinical-event evidence streams. By distinguishing between what PCSK9 inhibitors demonstrably achieve—potent LDL-C reduction and cardiovascular event prevention—and what remains speculative regarding lifespan extension, this synthesis offers a structured framework for evaluating the PCSK9 inhibitors longevity hypothesis. The clinical vs mechanistic separation we employ is intended to clarify where the evidence supports action and where it merely supports further investigation.","The geroscience hypothesis posits that fundamental aging processes underlie the pathogenesis of multiple chronic diseases, suggesting that targeting these shared mechanisms could yield broad healthspan benefits. This framework identifies interconnected biological hallmarks—including chronic inflammation, oxidative stress, cellular senescence, and metabolic dysregulation—that collectively drive age-related functional decline and multimorbidity. The proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitors longevity) pathway intersects several of these hallmarks, initially characterized for its role in hepatic low-density lipoprotein receptor degradation. Regulatory bodies approved PCSK9 inhibitors longevity primarily for cardiovascular risk reduction in patients with familial hypercholesterolemia or established atherosclerotic disease. However, the broader question of whether sustained LDL-C reduction via this mechanism confers longevity-relevant benefits beyond atherosclerosis remains an active area of investigation, with implications for how lipid-lowering agents might be repurposed within a geroscience-informed therapeutic strategy.","Several methodological questions bear on the interpretation of the PCSK9 inhibitors longevity evidence base for longevity-relevant outcomes. A fundamental concern is the reliance on surrogate endpoints such as LDL-C reduction and composite cardiovascular events rather than all-cause mortality or healthspan measures, which introduces uncertainty about whether biomarker improvements translate to meaningful longevity gains (Ioannidis 2005). Substantial heterogeneity exists across trials in populations studied, baseline cardiovascular risk, treatment durations, and concurrent interventions including statin intensity, complicating pooled effect estimation (Bruggen 2024). The tension between mechanistic plausibility—supported by preclinical observations of anti-inflammatory and endothelial-protective effects—and the mixed clinical mortality data (Ma 2025; Steg 2019; Wang 2022b) underscores the mechanism-to-clinic translation gap. Future investigations would benefit from longer treatment durations, aging-specific endpoints such as functional status and multimorbidity progression, and explicit assessment of concurrent lifestyle or pharmacological interventions that may modify PCSK9 inhibitors longevity effects.","Quantitative findings across these sources reveal a mixed cardiometabolic signal. By contrast, Bruggen 2024 identified a statistically significant baseline imbalance favoring placebo in trial populations, with BMI differences reaching significance (P = 0.03). Effect sizes and their exact magnitudes are summarized in the evidence synthesis for individual study–endpoint pairs.","Within the cardiometabolic corpus, several tensions emerge that temper the strength of the evidence. Liu 2023 reported null findings on direct cardiometabolic endpoints despite demonstrating mechanistic plausibility in endothelial cells, contrasting with Wang 2022, which reported an unclear overall effect direction across its network meta-analysis. Bruggen 2024 documented negative signals through identification of baseline imbalances that could confound trial outcomes, while Azizzadeh 2026 reported null findings at the observational cohort level. The disagreement between Bruggen 2024, which flagged potential methodological concerns in trial design, and Wang 2022, which reported favorable mortality reductions, highlights the importance of scrutinizing trial-level heterogeneity. These cross-study discrepancies underscore that the cardiometabolic case for PCSK9 inhibitors as longevity agents remains context-dependent and unresolved.","This discrepancy between null pharmacokinetic findings in healthy volunteers and positive clinical outcomes in patients with cardiovascular disease reflects a broader challenge in translating early-phase data to clinical practice. The observational cohort design of the pharmacokinetic study limits direct comparison with the randomized controlled trial data, yet both contribute essential pieces to the overall efficacy-safety profile. Future research integrating long-term pharmacokinetic data with hard clinical endpoints, such as mortality and cardiovascular event reduction, will be necessary to fully characterize the dose-response relationship relevant to longevity outcomes. Currently, the evidence supports robust LDL-C lowering but leaves open questions about optimal dosing for anti-aging benefits.","Quantitative findings from this preclinical work demonstrated a significant modulation of inflammatory and stress responses. The effect direction was null with respect to a simple anti-inflammatory interpretation, suggesting a more complex, context-dependent mechanism mediated by SIRT3. This indicates that the benefits of PCSK9 inhibition on cellular inflammation are not straightforward but depend on specific molecular contexts. The SIRT3-mediated pathway represents a plausible biological bridge between PCSK9 inhibition and longevity-associated cellular processes.","Mechanistically, the SIRT3-mediated pathway connects PCSK9 inhibition to fundamental processes in cellular aging. SIRT3 is a key regulator of mitochondrial function, which is central to theories of aging and cellular senescence. By demonstrating that a PCSK9 inhibitor can influence this pathway in endothelial cells, the preclinical data from DOnofrio 2023 provide a conceptual link between cholesterol management and broader longevity biology. The indirectness of this evidence, however, is substantial; the findings derive from a cell culture model using a supraphysiological concentration of evolocumab (100 µg/mL) and an inflammatory stimulus (IL-6 at 20 ng/mL) that may not fully replicate in vivo conditions. This mechanistic plausibility is a necessary but insufficient component of the longevity case for PCSK9 inhibitors.","Within the curated corpus, the immune outcome class is represented by a single preclinical study, creating a tension between mechanistic promise and the absence of corroborating human data. No human clinical trials testing immune or inflammatory endpoints as primary outcomes for PCSK9 inhibitors were identified in this synthesis. Therefore, while the preclinical signal is positive and mechanistically coherent, the evidence base is too sparse to draw conclusions about immune-mediated longevity effects in humans. This represents a critical gap where the biological rationale is not yet matched by clinical investigation.","Quantitative findings from this pilot trial must be interpreted with caution given its small sample size and exploratory design. The study enrolled 60 participants, a number insufficient for definitive efficacy conclusions but adequate for mechanistic proof-of-concept. Detailed effect sizes, p-values, and confidence intervals for inflammatory biomarker endpoints are presented in the evidence synthesis (Per-Study Endpoint Evidence). The absence of large-scale RCTs or cohort studies with hard inflammatory endpoints means the quantitative signal remains preliminary."]}